At a quick glance, the Food and Drug Administration’s decision to ask its advisers for help in vetting yet another cancer immunotherapy may seem odd. …
Gilead lost several billion dollars in market value Wednesday after unnerving investors with updates about a key clinical trial of its most closely watched breast …
Gilead lost several billion dollars in market value Wednesday after unnerving investors with updates about a key clinical trial of its most closely watched breast …
Dive Brief: The Food and Drug Administration on Tuesday granted approval to the first drug for a rare cancer of the eye that has spread …
Dive Brief: Incyte is pulling its application for an experimental lymphoma medicine after determining that the Food and Drug Administration’s requirements for confirmatory studies would …
Dive Brief: EQRx, which aims to bring new medicines to market at “radically lower” prices, said the experimental lung cancer drug it co-owns with Chinese …
The Food and Drug Administration has cleared Allogene Therapeutics to resume testing its cancer cell therapies after determining the company’s technology wasn’t to blame for …
Bristol Myers’ acquisition of Celgene immediately made the big pharma a top player in the development of cancer cell therapies. Since the deal closed, Bristol …
CAR-T cell therapies have demonstrated tremendous success in relapsed or refractory haematological malignancies. Now therapeutics companies and academics alike are racing to break through the …
Breast cancer is the most common cancer amongst women accounting for 24 percent of new cancer cases worldwide and 15 percent of cancer deaths in …
Novartis’ testing of canakinumab, which works by curbing inflammatory signaling in cells, for the seemingly unrelated use in lung cancer stems from an intriguing 2011 …
The theoretical risk that gene therapy may cause cancer in humans has hung over the field for decades. Those worries resurfaced last year when a …
Adaptimmune, like companies such as Bluebird Bio and Cellectis, remains one of the more prominent independent developers of cancer cell therapies. Early pioneers Kite Therapeutics …
GSK has high hopes for Jemperli as it transitions to what’s being called the “new GSK,” with a greater focus on experimental drugs for infectious …
In what has become a common move by large pharmaceutical companies attempting to revitalize their drug research, German healthcare conglomerate Bayer has acquired a small …
In an era of cancer immunotherapy, vaccines are getting fresh consideration as a therapeutic approach. Frustrated for years by lackluster results, cancer vaccine research is …
Oncology already sits as the top-selling therapeutic area on the orphan drug market, but a new report predicts it to account for even more — …
Partnership will enable women in Singapore, Malaysia, Vietnam, Brunei and Myanmar to access the benefits of MammaPrint® and BluePrint® to personalize treatment management decisions for …
The discovery has enhanced the understanding of dopamine receptors in carcinogenesis A team at Hong Kong Baptist University has developed the world’s first iridium (III)-based …
